Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients

被引：0

作者：

Huang, Chin-Chou ^{[1
,2
,3
,4
,5
]}

Charng, Min-Ji ^{[2
,3
]}

机构：

[1] Taipei Vet Gen Hosp, Dept Med Educ, 201,Sec 2,Shih Pai Rd, Taipei 11217, Taiwan

[2] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, 201,Sec 2,Shih Pai Rd, Taipei 11217, Taiwan

[3] Natl Yang Ming Univ, Fac Med, Sch Med, Taipei, Taiwan

[4] Natl Yang Ming Univ, Cardiovasc Res Ctr, Taipei, Taiwan

[5] Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan

来源：

THERAPEUTICS AND CLINICAL RISK MANAGEMENT | 2019年 / 15卷

关键词：

Chinese; evolocumab; homozygous familial hypercholesterolemia; low-density lipoprotein; proprotein convertase subtilisin/kexin type 9; AMG; 145; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; PCSK9; INHIBITION;

D O I：

10.2147/TCRM.S193971

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Evolocumab, which can lower low-density lipoprotein (LDL) cholesterol levels by approximately 60% and prevent cardiovascular events in patients with cardiovascular disease, is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Some studies have investigated its efficacy and safety in the treatment of the homozygous form of familial hypercholesterolemia (HoFH), and others have focused on its efficacy and safety in Asians with high cardiovascular risk. Although no direct evolocumab clinical trials have been conducted in Chinese HoFH patients, its efficacy and safety in the Chinese population should be similar to those in other ethnic groups.

引用

页码：1209 / 1216

页数：8

共 50 条

[21] Managing Patients With Homozygous Familial Hypercholesterolemia
Gidding, Samuel S.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (09) : 1171 - 1172
[22] Long-Term Evolocumab in Patients With Familial Hypercholesterolemia
Santos, Raul D.
Stein, Evan A.
Hovingh, G. Kees
Blom, Dirk J.
Soran, Handrean
Watts, Gerald F.
Lopez, J. Antonio G.
Bray, Sarah
Kurtz, Christopher E.
Hamer, Andrew W.
Raal, Frederick J.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (06) : 565 - 574
[23] Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia
Buonuomo, Paola Sabrina
Mastrogiorgio, Gerarda
Leone, Giovanna
Rana, Ippolita
Gonfiantini, Michaela Veronika
Macchiaiolo, Marina
Vecchio, Davide
Gnazzo, Maria
Bartuli, Andrea
ATHEROSCLEROSIS, 2021, 324 : 148 - 150
[24] Clinical value of myocardial perfusion imaging in patients with homozygous familial hypercholesterolemia
Jiao, J.
Wang, Q.
Mou, T.
Wang, L.
Mi, H.
Zhang, X.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S188 - S189
[25] LIVER TRANSPLANTATION AS A TREATMENT FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Kanmaz, Turan
Yankol, Yucel
Karatas, Cihan
Mecit, Nesimi
Orug, Taner
Acarli, Koray
Kalayoglu, Munci
PEDIATRIC TRANSPLANTATION, 2011, 15 : 97 - 97
[26] Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
Ito, Matthew K.
Watts, Gerald F.
DRUGS, 2015, 75 (15) : 1715 - 1724
[27] Homozygous familial hypercholesterolemia and its treatment by inclisiran
Marais, A. David
Blom, Dirk J.
Raal, Frederick J.
EXPERT OPINION ON ORPHAN DRUGS, 2020, 8 (06): : 197 - 207
[28] Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia
Kolansky, Daniel M.
Cuchel, Marina
Clark, Bernard J.
Paridon, Steve
McCrindle, Brian W.
Wiegers, Susan E.
Araujo, Luis
Vohra, Yogesh
Defesche, Joep C.
Wilson, James M.
Rader, Daniel J.
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (11): : 1438 - 1443
[29] HEMODYNAMIC AND ANGIOGRAPHIC EVALUATION OF CARDIOVASCULAR INVOLVEMENT IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
PISCIONE, F
CAPPELLIBIGAZZI, M
POSTIGLIONE, A
GNASSO, A
FOCACCIO, A
CHIARIELLO, M
CORONARY ARTERY DISEASE, 1990, 1 (06) : 725 - 731
[30] Current Treatment Options in Homozygous Familial Hypercholesterolemia
Kayikcioglu, Meral
Tokgozoglu, Lale
PHARMACEUTICALS, 2023, 16 (01)

← 1 2 3 4 5 →